SELECT trial (revision 2)
Old revision·15:34, 9 Aug 2024·DataTableDunja
This is an old revision of this page, as it stood at 15:34, 9 Aug 2024, saved by DataTableDunja with the summary add the number randomised and the number completing. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| SELECT trial | |
|---|---|
| Drug | Semaglutide 2.4 mg weekly |
| Population | Established CVD, BMI ≥27, no diabetes |
| Participants | 17,604 |
| Primary result | MACE HR 0.80 (95% CI 0.72–0.90) |
| Topic infobox · conventions | |
SELECT was a randomised, double-blind, placebo-controlled cardiovascular outcome trial of weekly semaglutide 2.4 mg in 17,604 adults with established cardiovascular disease and a body-mass index of 27 or above, and without diabetes.[1]
The primary composite outcome — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months, a hazard ratio of 0.80 (95% CI 0.72–0.90).[1]